Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJ. Clin. Oncol 2021 Nov 24;[EPub Ahead of Print], JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, CL Cowey, D Schadendorf, J Wagstaff, R Dummer, PF Ferrucci, M Smylie, MO Butler, A Hill, I Márquez-Rodas, JBAG Haanen, M Guidoboni, M Maio, P Schöffski, MS Carlino, C Lebbé, G McArthur, PA Ascierto, GA Daniels, GV Long, T Bas, C Ritchings, J Larkin, FS Hodi
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.